J&J is about to make a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs in Kendall Square for one of its four global innovation centers--putting it right in the heart of one of the busiest biotech regions in the world.
Johnson & Johnson's DePuy unit is recalling the diaphyseal sleeve shipped with its Limb Preservation System, warning that the sleeve may fracture as patients walk, possibly resulting in infection or loss of limb.
An Iowa woman is suing Stryker for safety problems over Stryker's now-recalled Rejuvenate metal-on-metal hip implant.
Johnson & Johnson scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and now Abbott Laboratories is stepping in to develop a companion diagnostic for the headline-grabbing compound.
Already reeling from thousands of lawsuits in the U.S. over faulty ASR-model hips, J&J is now warning doctors overseas to stop using another implant it once sold because of reliability issues.
Johnson & Johnson is facing thousands of lawsuits over its Prolift vaginal mesh implant, and lawyers for the plaintiffs say the company was warned of problems with the devices long before it chose to sell them anyway.
Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib.
J&J and Pharmacyclics nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year.
A San Francisco Chronicle story renews calls for the FDA to close loopholes that allow devices such as all-metal artificial hips to win 510(k) clearance, and avoid human testing before approval as a result.
Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report